Patient Rating:

No Rating Available?

Matthew T. Rondina, M.D., M.S.

Patient Rating:

No Rating Available?



  • English

Clinical Details

Phone Number Clinical Office Address
(801) 581-7790
Madsen Health Center
555 Foothill Blvd
Salt Lake City, UT 84112



I have been a faculty member of the University of Utah Department of Medicine since 2006, where I first served as Chief Medical Resident. My clinical practice is focused on the prevention and treatment of thrombotic disorders, including deep vein thrombosis, pulmonary embolism, stroke, and peripheral vascular disease. I teach students and residents about these disorders and speak nationally on these topics. I also serve on national committees focused on the prevention and treatment of thrombotic disease.

I grew up in Boston and completed my training at the University of Utah in 2006. I subsequently completed a Masters of Science in Clinical Investigation (MSCI) degree through the University of Utah Center for Clinical and Translational Science (CCTS). I have also volunteered for global health in Kenya, lectured annually on thrombotic disorders for the Molecular Medicine Course, and serve as a regular mentor for the T35 Medical Student Research Program at the University of Utah.

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor
Academic Divisions General Internal Medicine
Board Certification American Board of Internal Medicine (Internal Medicine)

Academic Profile

Board Certification and Academic Information

Academic Departments Internal Medicine - Associate Professor
Academic Divisions General Internal Medicine
Board Certification American Board of Internal Medicine (Internal Medicine)

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 585-0950 George and Dolores Eccles Institute of Human Genetics
University Health Care - Internal Medicine
15 N 2030 E
Salt Lake City, UT 84112

Academic Bio

Our research program focuses on platelet and megakaryocyte functions in infectious and inflammatory disorders where thrombosis is common. The majority of our research, physically housed within the Molecular Medicine Program in the Eccles Institute of Human Genetics, is NIH-funded and utilizes primary human cells and samples from patients as well as relevant animal models. Our research program currently includes studies in sepsis, cardiometabolic disorders, and aging. We have contributed to an understanding of novel functions of platelets, megakaryocyte, and platelet-leukocyte interactions during health and disease.

I have also assisted with the development of institutional and extramural clinical care pathways to improve the prevention and treatment of thrombotic diseases. I have been fortunate to receive recognition for our research, including being named as a 2011 GEMSSTAR Scholar, and receiving the 2012 William D. O’Dell Young Investigator Award, the 2013 American Society of Clinical Investigation (ASCI) Young Physician-Scientist Award, and the 2013 University of Utah Golden Anniversary Prize for Clinical Investigation.

I have mentored numerous trainees and junior faculty. I also serve regularly on NIH, AHA, and CHIR study sections, engage in collaborative international research with investigators in Brazil, China, Germany, and other countries and am Director of the Precision Medicine Foundation of the University of Utah Center for Clinical and Translational Science.


Education History

Type School Degree
Graduate Training University of Utah
Clinical Investigation
Residency University of Utah Health Sciences Center
Internal Medicine
Internship University of Utah Health Sciences Center
Internal Medicine
Professional Medical University of Utah Medical School
Undergraduate University of Utah
Undergraduate Brigham Young University


Selected Provider Publications

Journal Article

  1. Rondina MT, Graves KK (2016). The addition of abdomen and pelvis CT to limited cancer screening does not increase diagnosis of cancer in patients with unprovoked venous thromboembolism. Evid Based Med, 21(1), 19.
  2. Woller SC, Stevens SM, Kaplan DA, Branch DW, Aston VT, Wilson EL, Gallo HM, Johnson EG, Rondina MT, Lloyd JF, Evans RS, Elliott CG (2016). Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). Clin Appl Thromb Hemost, 22(3), 239-47.
  3. Rondina MT, Tatsumi K, Bastarache JA, Mackman N (2016). Microvesicle Tissue Factor Activity and Interleukin-8 Levels are Associated with Mortality in Patients with Influenza A/H1N1 Infection. (Epub ahead of print) Crit Care Med.
  4. Rondina MT, Freitag M, Pluthero FG, Kahr WH, Rowley JW, Kraiss LW, Franks Z, Zimmerman GA, Weyrich AS, Schwertz H (2016). Non-genomic activities of retinoic acid receptor alpha control actin cytoskeletal events in human platelets. J Thromb Haemost, 14(5), 1082-94.
  5. Stubblefield WB, Alves NJ, Rondina MT, Kline JA (2016). Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism. PLoS One, 11(2), e0148747.
  6. Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, Lentaigne C, Schulman S, Sivapalaratnam S, Vries MJ, Westbury SK, Greene D, Papadia S, Alessi MC, Attwood AP, Ballmaier M, Baynam G, Bermejo E, Bertoli M, Bray PF, Bury L, Cattaneo M, Collins P, Daugherty LC, Favier R, French DL, Furie B, Gattens M, Germeshausen M, Ghevaert C, Goodeve AC, Guerrero JA, Hampshire DJ, Hart DP, Heemskerk JW, Henskens YM, Hill M, Hogg N, Jolley JD, Kahr WH, Kelly AM, Kerr R, Kostadima M, Kunishima S, Lambert MP, Liesner R, Lopez JA, Mapeta RP, Mathias M, Millar CM, Nathwani A, Neerman-Arbez M, Nurden AT, Nurden P, Othman M, Peerlinck K, Perry DJ, Poudel P, Reitsma P, Rondina MT, Smethurst PA, Stevenson W, Szkotak A, Tuna S, van Geet C, Whitehorn D, Wilcox DA, Zhang B, Revel-Vilk S, Gresele P, Bellissimo DB, Penkett CJ, Laffan MA, Mumford AD, Rendon A, Gomez K, Freson K, Ouwehand WH, Turro E (2016). A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 127(23), 2791-803.
  7. Shih L, Kaplan D, Kraiss LW, Casper TC, Pendleton RC, Peters CL, Supiano MA, Zimmerman GA, Weyrich AS, Rondina MT (2016). Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients. Sci Rep, 6, 27478.
  8. Xu J, Yang YZ, Tang F, Ga Q, Wuren T, Wang Z, Ma L, Rondina MT, Ge RL (2015). CYP17A1 and CYP2E1 variants associated with high altitude polycythemia in Tibetans at the Qinghai-Tibetan Plateau. Gene, 566(2), 257-63.
  9. Rondina MT, Weyrich AS (2015). Dengue virus pirates human platelets. Blood, 126(3), 286-7.
  10. Vazquez S, Rondina MT (2015). Direct oral anticoagulants (DOACs). Vascular Medicine, 20(6), 575-7.
  11. Watkins RD, Rondina MT (2015). ACP Journal Club. Review: DOACs do not differ from standard anticoagulants for recurrent VTE; factor Xa inhibitors reduce bleeding. Ann Intern Med, 163(8), JC3.
  12. Su J, Li Z, Cui S, Ji L, Geng H, Chai K, Ma X, Bai Z, Yang Y, Wuren T, Ge RL, Rondina MT (2015). The Local HIF-2alpha/EPO Pathway in the Bone Marrow is Associated with Excessive Erythrocytosis and the Increase in Bone Marrow Microvessel Density in Chronic Mountain Sickness. High Alt Med Biol, 16(4), 318-30.
  13. Brown SM, Grissom CK, Rondina MT, Hoidal JR, Scholand MB, Wolff RK, Morris AH, Paine R 3rd (2015). Polymorphisms in key pulmonary inflammatory pathways and the development of acute respiratory distress syndrome. Exp Lung Res, 41(3), 155-162.
  14. Zhao YX, Tang F, Ga Q, Wuren T, Wang YP, Rondina MT, Ge RL (2015). High fat diet exacerbates vascular endothelial dysfunction in rats exposed to continuous hypobaric hypoxia. Biochem Biophys Res Commun, 457(3), 485-91.
  15. Brown SM, Tate MQ, Jones JP, Kuttler KG, Lanspa MJ, Rondina MT, Grissom CK, Mathews VJ (2015). Coefficient of Variation of Coarsely Sampled Heart Rate is Associated With Early Vasopressor Independence in Severe Sepsis and Septic Shock. J Intensive Care Med, 30(7), 420-5.
  16. Stewart LK, Peitz GW, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Kline JA (2014). Contribution of fibrinolysis to the physical component summary of the SF-36 after acute submassive pulmonary embolism. (Epub ahead of print) J Thromb Thrombolysis.
  17. Rondina MT, Carlisle M, Fraughton T, Brown SM, Miller RR 3rd, Harris ES, Weyrich AS, Zimmerman GA, Supiano MA, Grissom CK (07/29/2014). Platelet-Monocyte Aggregate Formation and Mortality Risk in Older Patients With Severe Sepsis and Septic Shock. J Gerontol A Biol Sci Med Sci, In Press.
  18. Madden JL, Drakos SG, Stehlik J, McKellar SH, Rondina MT, Weyrich AS, Selzman CH (2014). Baseline red blood cell osmotic fragility does not predict the degree of post-LVAD hemolysis. ASAIO J, 60(5), 524-8.
  19. Cook RM, Rondina MT, Horton DJ (2014). Rivaroxaban for the Long-term Treatment of Spontaneous Ovarian Vein Thrombosis Caused by Factor V Leiden Homozygosity. Ann Pharmacother, 48(8), 1055-1060.
  20. Johnson SA, Rondina MT (2014). Edoxaban was noninferior to warfarin for preventing stroke or systemic embolism in atrial fibrillation. Ann Intern Med, 160(6), JC7.
  21. Mohebali D, Kaplan D, Carlisle M, Supiano MA, Rondina MT (2014). Alterations in platelet function during aging: clinical correlations with thromboinflammatory disease in older adults. J Am Geriatr Soc, 62(3), 529-35.
  22. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J (2014). Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost, 12(4), 459-68.
  23. Brown SM, Tate Q, Jones JP, Knox DB, Kuttler KG, Lanspa M, Rondina MT, Grissom CK, Behera S, Mathews VJ, Morris A (2013). Initial fractal exponent of heart rate variability is associated with success of early resuscitation in patients with severe sepsis or septic shock: a prospective cohort study. J Crit Care, 28(6), 959-63.
  24. Vazquez S, Rondina MT (2013). Apixaban reduced stroke or systemic embolism in AF more than warfarin regardless of type or duration of AF. Ann Intern Med, 159(2), JC8.
  25. Rondina MT, Weyrich AS, Zimmerman GA (2013 May 24). Platelets as cellular effectors of inflammation in vascular disease. Circ Res, 112(11), 1506-19.
  26. Chen K, Rondina MT, Weyrich AS (2013). A sticky story for signal transducer and activator of transcription 3 in platelets. Circulation, 127(4), 421-3.
  27. Rondina MT, Lam UT, Pendleton RC, Kraiss LW, Wanner N, Zimmerman GA, Hoffman JM, Hanrahan C, Boucher K, Christian PE, Butterfield RI, Morton KA (2012). (18)F-FDG PET in the evaluation of acuity of deep vein thrombosis. Clin Nucl Med, 37(12), 1139-45.
  28. McInturff AM, Cody MJ, Elliott EA, Glenn JW, Rowley JW, Rondina MT, Yost CC (2012). Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 alpha. Blood, 120(15), 3118-25.
  29. Kraemer BF, Campbell RA, Schwertz H, Franks ZG, Vieira de Abreu A, Grundler K, Kile BT, Dhakal BK, Rondina MT, Kahr WH, Mulvey MA, Blaylock RC, Zimmerman GA, Weyrich AS (2012). Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. Blood, 120(25), 5014-20.
  30. Freeman A, Horner T, Pendleton RC, Rondina MT (2012). Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol, 87(7), 740-3.
  31. Rondina MT, Grissom CK, Men S, Harris ES, Schwertz H, Zimmerman GA, Weyrich AS (2012). Whole blood flow cytometry measurements of in vivo platelet activation in critically-Ill patients are influenced by variability in blood sampling techniques. Thromb Res, 129(6), 729-35.
  32. Rondina MT, Brewster B, Grissom CK, Zimmerman GA, Kastendieck DH, Harris ES, Weyrich AS (2012). In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest, 141(6), 1490-5.
  33. Rondina MT, Wanner N, Pendleton RC, Kraiss LW, Vinik R, Zimmerman GA, Heilbrun M, Hoffman JM, Morton KA (2011). A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res, 129(1), 22-7.
  34. Rondina MT, Schwertz H, Harris ES, Kraemer BF, Campbell RA, Mackman N, Grissom CK, Weyrich AS, Zimmerman GA (2011). The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost, 9(4), 748-58.
  35. Johnson S, Rondina MT (2011). Local INR control had some effect on the benefits of dabigatran over warfarin for major bleeding in atrial fibrillation. ACP J Club, 154(2), JC1-6.
  36. Vazquez SR, Johnson SA, Rondina MT (2010). Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb Res, 126(2), e69-77.
  37. Rondina MT, Walker A, Pendleton RC (2010). Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia. Hosp Pract (Minneap), 38(2), 19-28.
  38. Freeman AL, Pendleton RC, Rondina MT (2010). Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther, 8(12), 1711-21.
  39. Vazquez S, Rondina MT (2010). ACP Journal Club. Review: Graduated compression stockings reduce deep venous thrombosis in hospitalized patients. Ann Intern Med, 153(12), JC6-6.
  40. Franks ZG, Campbell RA, Weyrich AS, Rondina MT (2010). Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke. Ann N Y Acad Sci, 1207, 11-7.
  41. Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC (2010). Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res, 125(3), 220-223.


  1. Franks Z, Carlisle M, Rondina MT (2015). Current challenges in understanding immune cell functions during septic syndromes. [Review]. BMC Immunol, 16, 11.
  2. Rondina MT, Weyrich AS (2015). Regulation of the genetic code in megakaryocytes and platelets. [Review]. J Thromb Haemost, 13 Suppl 1, S26-32.
  3. Edholm K, Ragle N, Rondina MT (2015). Antithrombotic Management of Atrial Fibrillation in the Elderly. [Review]. Med Clin North Am, 99(2), 417-430.

Book Chapter

  1. Rondina MT, Weyrich AS (2012). Targeting Phosphodiesterases in Anti-Platelet Therapy. In Gresele, P. (Eds.), Antiplatelet Agents, Handbook of Experimental Pharmacology (210, pp. 225-38). Berlin: Springer-Verlag.
  2. Harris ES, Rondina MT, Schwertz H, Weyrich AS, Zimmerman GA (2010). Pathogenesis of sepsis and sepsis-induced acute lung injury. In A.M.K. Choi (Ed.), Acute Respiratory Distress Syndrome, Second Edition (pp. 369-419). Informa Healthcare.


  1. Rondina MT, Lam UT, Pendleton RC, Kraiss LW, Wanner N, Zimmerman GA, Hanrahan C Boucher K, Hoffman M, Morton KA (04/22/2012). The role of 18-fluorine-fluorodeoxyglucose positron emission tomography in the evaluation of deep vein thrombosis [Abstract]. Thrombosis Research, 129(S1), S165.


  1. Schwertz H, Rondina MT, Weyrich AS (2014). Retinoic acid receptor alpha guides platelet actin cytoskeleton dynamics. Poster session presented at 8th International Platelet Symposium, Jerusalem, Israel.
  2. Schwertz HJ, Rondina MT, Weyrich AS (February 13, 2014). Retinoic Acid Receptor Alpha Guides Platelet Actin Cytoskeletal Dynamics (P22-5). Poster session presented at 58th Annual Meeting Society of Thrombosis and Haemostasis Research, Vienna, Austria.
  3. Rondina MT, Kalva S, Men S, Harris ES, Carlisle M, Zimmerman GA, Weyrich AS, Grissom CK (2012). Platelet-Monocyte Aggregate Formation and Cytokine Responses Correlate with Mortality in Elderly Septic Patients. Poster session presented at 2012 American Geriatric Society National Meeting, Seattle, WA.

Clinical Trials

Video & News